Breast

 

 Node Positive (1-3 nodes), HR pos, HER2-neg

  • SWOG S1007: Rx PONDER Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer 

 

Stage IV

 

  • CTSU E2108: Early Surgery or Sta​ndard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
  • E2112:  Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic

Neo-Adjuvant

  •  Alliance  A011106:  Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
  • BERENICE:    A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.

TNBC & HR+/HER2- with Germline BRCA Mutations

 

  •  NSABP B-55:  A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
  • For more information, contact Cheryl Patz, RN, OCN, CCRC, at 360-788-8238.​​​​